Neuronetics Historical Financial Ratios

STIM Stock

USD 4.67 0.19 3.91%

Neuronetics is lately reporting on over 100 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Capex To Depreciation of 0.91, Pb Ratio of 1.94, Inventory Turnover of 3.78 or Payables Turnover of 3.12 will help investors to properly organize and evaluate Neuronetics financial condition quickly.

Quick Ratio Current Ratio

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.

About Neuronetics Financial Ratios Analysis

NeuroneticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Neuronetics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Neuronetics financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Neuronetics history.

Neuronetics Financial Ratios Chart

At this time, Neuronetics' Book Value Per Share is very stable compared to the past year. As of the 25th of March 2025, EV To Sales is likely to grow to 1.13, while PTB Ratio is likely to drop 1.94.

Price To Sales Ratio Free Cash Flow Yield Roic Inventory Turnover Payables Turnover

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Neuronetics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Neuronetics sales, a figure that is much harder to manipulate than other Neuronetics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Roic

Return on Invested Capital, a profitability ratio that measures the return that an investment generates for those who have provided capital, such as debt holders and equity holders.

Inventory Turnover

A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Most ratios from Neuronetics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Neuronetics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.At this time, Neuronetics' Book Value Per Share is very stable compared to the past year. As of the 25th of March 2025, EV To Sales is likely to grow to 1.13, while PTB Ratio is likely to drop 1.94.

	2022	2023	2024	2025 (projected)
Current Ratio	2.98	4.73	4.26	3.62
Intangibles To Total Assets	0.0308	0.0363	0.0326	0.0343

Current Ratio Intangibles To Total Assets

Neuronetics fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Payables Turnover	Capex To Revenue	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Income Quality	Roe	Pe Ratio	Return On Tangible Assets	Earnings Yield	Intangibles To Total Assets	Current Ratio	Receivables Turnover	Debt To Equity	Capex Per Share
Price To Sales Ratio		0.88	0.76	0.75	0.58	0.88	0.75	0.71	-0.25	0.74	-0.25	0.53	-0.98	-0.42	-0.3	-0.98	0.62	-0.65	-0.98	0.49	0.75	0.21	0.72	-0.45	0.5	-0.71
Ptb Ratio	0.88		0.71	0.7	0.31	1.0	0.7	0.59	-0.29	0.7	-0.28	0.35	-0.8	-0.17	-0.09	-0.81	0.61	-0.82	-0.81	0.35	0.7	0.37	0.48	-0.55	0.7	-0.67
Free Cash Flow Yield	0.76	0.71		1.0	0.6	0.71	1.0	0.94	-0.31	1.0	-0.36	0.64	-0.77	-0.48	-0.4	-0.77	0.6	-0.89	-0.77	0.83	1.0	0.65	0.72	-0.68	0.83	-0.98
Operating Cash Flow Per Share	0.75	0.7	1.0		0.6	0.7	1.0	0.94	-0.31	1.0	-0.37	0.64	-0.77	-0.48	-0.4	-0.77	0.6	-0.89	-0.76	0.84	1.0	0.66	0.72	-0.68	0.84	-0.98
Capex To Depreciation	0.58	0.31	0.6	0.6		0.31	0.6	0.67	-0.64	0.58	-0.05	0.95	-0.6	-0.72	-0.88	-0.57	0.31	-0.37	-0.56	0.61	0.59	0.44	0.65	-0.56	0.31	-0.52
Pb Ratio	0.88	1.0	0.71	0.7	0.31		0.7	0.59	-0.29	0.7	-0.28	0.35	-0.8	-0.17	-0.09	-0.81	0.61	-0.82	-0.81	0.35	0.7	0.37	0.48	-0.55	0.7	-0.67
Free Cash Flow Per Share	0.75	0.7	1.0	1.0	0.6	0.7		0.94	-0.31	1.0	-0.36	0.64	-0.77	-0.48	-0.4	-0.76	0.6	-0.89	-0.76	0.83	1.0	0.66	0.72	-0.68	0.84	-0.98
Roic	0.71	0.59	0.94	0.94	0.67	0.59	0.94		-0.27	0.93	-0.48	0.65	-0.76	-0.38	-0.46	-0.76	0.47	-0.79	-0.75	0.95	0.93	0.61	0.87	-0.62	0.77	-0.88
Inventory Turnover	-0.25	-0.29	-0.31	-0.31	-0.64	-0.29	-0.31	-0.27		-0.31	-0.23	-0.76	0.18	0.29	0.75	0.16	-0.08	0.33	0.16	-0.23	-0.3	-0.62	-0.18	0.78	-0.36	0.29
Net Income Per Share	0.74	0.7	1.0	1.0	0.58	0.7	1.0	0.93	-0.31		-0.35	0.63	-0.76	-0.47	-0.39	-0.76	0.6	-0.88	-0.76	0.82	1.0	0.65	0.7	-0.67	0.83	-0.99
Payables Turnover	-0.25	-0.28	-0.36	-0.37	-0.05	-0.28	-0.36	-0.48	-0.23	-0.35		0.14	0.24	-0.27	-0.33	0.26	-0.29	0.37	0.25	-0.45	-0.35	0.04	-0.6	-0.1	-0.36	0.31
Capex To Revenue	0.53	0.35	0.64	0.64	0.95	0.35	0.64	0.65	-0.76	0.63	0.14		-0.55	-0.72	-0.95	-0.52	0.32	-0.46	-0.52	0.6	0.64	0.64	0.52	-0.75	0.44	-0.59
Pocfratio	-0.98	-0.8	-0.77	-0.77	-0.6	-0.8	-0.77	-0.76	0.18	-0.76	0.24	-0.55		0.43	0.35	1.0	-0.57	0.61	1.0	-0.59	-0.77	-0.22	-0.78	0.42	-0.48	0.73
Interest Coverage	-0.42	-0.17	-0.48	-0.48	-0.72	-0.17	-0.48	-0.38	0.29	-0.47	-0.27	-0.72	0.43		0.64	0.41	-0.45	0.23	0.4	-0.26	-0.48	-0.22	-0.21	0.33	-0.09	0.46
Capex To Operating Cash Flow	-0.3	-0.09	-0.4	-0.4	-0.88	-0.09	-0.4	-0.46	0.75	-0.39	-0.33	-0.95	0.35	0.64		0.32	-0.08	0.22	0.31	-0.48	-0.39	-0.58	-0.37	0.65	-0.24	0.35
Pfcf Ratio	-0.98	-0.81	-0.77	-0.77	-0.57	-0.81	-0.76	-0.76	0.16	-0.76	0.26	-0.52	1.0	0.41	0.32		-0.57	0.61	1.0	-0.58	-0.76	-0.21	-0.78	0.41	-0.48	0.73
Income Quality	0.62	0.61	0.6	0.6	0.31	0.61	0.6	0.47	-0.08	0.6	-0.29	0.32	-0.57	-0.45	-0.08	-0.57		-0.53	-0.62	0.28	0.61	0.16	0.43	-0.38	0.46	-0.6
Roe	-0.65	-0.82	-0.89	-0.89	-0.37	-0.82	-0.89	-0.79	0.33	-0.88	0.37	-0.46	0.61	0.23	0.22	0.61	-0.53		0.61	-0.66	-0.88	-0.75	-0.49	0.72	-0.96	0.85
Pe Ratio	-0.98	-0.81	-0.77	-0.76	-0.56	-0.81	-0.76	-0.75	0.16	-0.76	0.25	-0.52	1.0	0.4	0.31	1.0	-0.62	0.61		-0.57	-0.76	-0.21	-0.78	0.42	-0.49	0.72
Return On Tangible Assets	0.49	0.35	0.83	0.84	0.61	0.35	0.83	0.95	-0.23	0.82	-0.45	0.6	-0.59	-0.26	-0.48	-0.58	0.28	-0.66	-0.57		0.82	0.63	0.83	-0.57	0.7	-0.78
Earnings Yield	0.75	0.7	1.0	1.0	0.59	0.7	1.0	0.93	-0.3	1.0	-0.35	0.64	-0.77	-0.48	-0.39	-0.76	0.61	-0.88	-0.76	0.82		0.65	0.71	-0.67	0.83	-0.99
Intangibles To Total Assets	0.21	0.37	0.65	0.66	0.44	0.37	0.66	0.61	-0.62	0.65	0.04	0.64	-0.22	-0.22	-0.58	-0.21	0.16	-0.75	-0.21	0.63	0.65		0.24	-0.86	0.84	-0.63
Current Ratio	0.72	0.48	0.72	0.72	0.65	0.48	0.72	0.87	-0.18	0.7	-0.6	0.52	-0.78	-0.21	-0.37	-0.78	0.43	-0.49	-0.78	0.83	0.71	0.24		-0.37	0.47	-0.65
Receivables Turnover	-0.45	-0.55	-0.68	-0.68	-0.56	-0.55	-0.68	-0.62	0.78	-0.67	-0.1	-0.75	0.42	0.33	0.65	0.41	-0.38	0.72	0.42	-0.57	-0.67	-0.86	-0.37		-0.76	0.64
Debt To Equity	0.5	0.7	0.83	0.84	0.31	0.7	0.84	0.77	-0.36	0.83	-0.36	0.44	-0.48	-0.09	-0.24	-0.48	0.46	-0.96	-0.49	0.7	0.83	0.84	0.47	-0.76		-0.8
Capex Per Share	-0.71	-0.67	-0.98	-0.98	-0.52	-0.67	-0.98	-0.88	0.29	-0.99	0.31	-0.59	0.73	0.46	0.35	0.73	-0.6	0.85	0.72	-0.78	-0.99	-0.63	-0.65	0.64	-0.8

Click cells to compare fundamentals

Neuronetics Account Relationship Matchups

Neuronetics fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Price To Sales Ratio	4.25	2.05	2.83	1.16	0.68	0.65
Ptb Ratio	8.21	1.33	3.24	2.43	2.19	1.94
Free Cash Flow Yield	(0.14)	(0.27)	(0.18)	(0.41)	(0.64)	(0.67)
Operating Cash Flow Per Share	(1.51)	(1.1)	(1.14)	(1.12)	(0.98)	(1.03)
Stock Based Compensation To Revenue	0.0894	0.14	0.13	0.1	0.0748	0.0576
Capex To Depreciation	0.78	2.22	1.98	1.18	0.71	0.91
Pb Ratio	8.21	1.33	3.24	2.43	2.19	1.94
Free Cash Flow Per Share	(1.55)	(1.19)	(1.26)	(1.2)	(1.03)	(1.08)
Roic	(0.4)	(0.25)	(0.38)	(0.31)	(0.28)	(0.3)
Inventory Turnover	3.11	1.78	1.74	2.43	2.79	3.78
Net Income Per Share	(1.71)	(1.4)	(1.46)	(1.05)	(1.37)	(1.43)
Payables Turnover	3.08	2.71	6.36	4.13	3.72	3.12
Sales General And Administrative To Revenue	0.28	0.37	0.46	0.39	0.36	0.4
Research And Ddevelopement To Revenue	0.16	0.22	0.19	0.14	0.13	0.17
Capex To Revenue	0.0148	0.0425	0.0501	0.0332	0.0196	0.0193
Pocfratio	(7.37)	(4.06)	(6.01)	(2.59)	(1.64)	(1.72)
Interest Coverage	(4.93)	(6.86)	(8.26)	(5.63)	(4.67)	(4.91)
Capex To Operating Cash Flow	(0.0257)	(0.0841)	(0.11)	(0.0739)	(0.0473)	(0.0497)
Pfcf Ratio	(7.19)	(3.75)	(5.43)	(2.42)	(1.57)	(1.65)
Income Quality	1.03	0.9	0.83	1.06	0.72	0.7
Roe	(1.27)	(0.42)	(0.69)	(0.88)	(1.02)	(1.07)
Pe Ratio	(6.48)	(3.19)	(4.71)	(2.75)	(1.18)	(1.24)
Earnings Yield	(0.15)	(0.31)	(0.21)	(0.36)	(0.85)	(0.89)
Intangibles To Total Assets	0.0153	0.0177	0.0308	0.0363	0.0326	0.0343
Current Ratio	4.75	7.34	2.98	4.73	4.26	3.62
Receivables Turnover	6.87	7.11	4.72	4.0	4.6	8.34
Debt To Equity	1.5	0.46	0.7	1.83	1.64	1.73
Capex Per Share	0.0388	0.0924	0.12	0.0827	0.0464	0.044
Revenue Per Share	2.61	2.17	2.42	2.49	2.37	2.25
Debt To Assets	0.34	0.49	0.28	0.54	0.62	0.53
Days Sales Outstanding	53.11	51.34	77.37	91.26	82.13	42.69
Book Value Per Share	1.35	3.34	2.12	1.19	1.07	1.13
Ev To Sales	4.03	1.07	2.36	1.2	1.08	1.13
Days Of Inventory On Hand	117.52	205.57	209.79	150.38	135.34	100.74
Cash Per Share	2.7	3.78	2.67	2.11	2.43	2.31
Days Payables Outstanding	118.43	134.66	57.36	88.3	101.55	109.38
Ev To Operating Cash Flow	(7.0)	(2.11)	(5.02)	(2.68)	(3.08)	(3.24)
Ev To Free Cash Flow	(6.82)	(1.95)	(4.53)	(2.5)	(2.87)	(3.01)
Net Debt To E B I T D A	1.54	0.5	2.06	0.98	(0.12)	(0.11)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Neuronetics is a strong investment it is important to analyze Neuronetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neuronetics' future performance. For an informed investment choice regarding Neuronetics Stock, refer to the following important reports:

How To Invest In Neuronetics

Details

Is Neuronetics Stock a good investment?

Details

What is Neuronetics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.

You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuronetics. If investors know Neuronetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuronetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.37)

Revenue Per Share

2.368

Quarterly Revenue Growth

0.107

Return On Assets

(0.17)

Return On Equity

(1.48)

The market value of Neuronetics is measured differently than its book value, which is the value of Neuronetics that is recorded on the company's balance sheet. Investors also form their own opinion of Neuronetics' value that differs from its market value or its book value, called intrinsic value, which is Neuronetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuronetics' market value can be influenced by many factors that don't directly affect Neuronetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Neuronetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuronetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuronetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Free Cash Flow Yield
Operating Cash Flow Per Share	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Free Cash Flow Per Share	Roic
Inventory Turnover	Net Income Per Share
Payables Turnover	Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue	Capex To Revenue
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Income Quality
Roe	Pe Ratio
Return On Tangible Assets	Earnings Yield
Intangibles To Total Assets	Current Ratio
Receivables Turnover	Debt To Equity
Capex Per Share	Revenue Per Share
Debt To Assets	Days Sales Outstanding
Book Value Per Share	Invested Capital
Average Payables	Ev To Sales
Days Of Inventory On Hand	Average Inventory
Cash Per Share	Days Payables Outstanding
Net Current Asset Value	Tangible Asset Value
Ev To Operating Cash Flow	Ev To Free Cash Flow
Net Debt To E B I T D A	Tangible Book Value Per Share
Shareholders Equity Per Share	Graham Net Net
Average Receivables	Interest Debt Per Share
Enterprise Value Over E B I T D A	Short Term Coverage Ratios
Price Earnings Ratio	Price Book Value Ratio
Price Earnings To Growth Ratio	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Operating Cash Flow Sales Ratio	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Debt Ratio
Cash Flow To Debt Ratio	Price Sales Ratio
Return On Assets	Asset Turnover
Net Profit Margin	Gross Profit Margin
Price Fair Value	Return On Equity
Operating Cycle	Days Of Payables Outstanding
Cash Conversion Cycle	Days Of Inventory Outstanding
Days Of Sales Outstanding	Enterprise Value Multiple

Neuronetics Historical Financial Ratios

About Neuronetics Financial Ratios Analysis

Neuronetics Financial Ratios Chart

Price To Sales Ratio

Free Cash Flow Yield

Roic

Inventory Turnover

Payables Turnover

Neuronetics fundamentals Correlations

Neuronetics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Neuronetics fundamentals Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Operating Cash Flow Per Share	+ 1.0	Free Cash Flow Yield
Free Cash Flow Per Share	+ 1.0	Free Cash Flow Yield
Net Income Per Share	+ 1.0	Free Cash Flow Yield
Earnings Yield	+ 1.0	Free Cash Flow Yield
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share

Capex Per Share	- 0.99	Earnings Yield
Capex Per Share	- 0.99	Net Income Per Share
Capex Per Share	- 0.98	Free Cash Flow Per Share
Capex Per Share	- 0.98	Operating Cash Flow Per Share
Capex Per Share	- 0.98	Free Cash Flow Yield
Pe Ratio	- 0.98	Price To Sales Ratio